When hyaluronic acid (HA) filler blocks an artery supplying the eye, reopening the vessel does not reliably restore sight. That is the central finding of an international review of 200 cases treated through a catheter, published online on 6 November in Aesthetic Surgery Journal Open Forum. The authors, from an international task force on vision complications, also propose new treatment protocols.
Filler-induced blindness is rare but devastating. Filler can travel backwards from facial arteries into the ophthalmic artery and cut off blood to the retina. Injecting hyaluronidase, which dissolves HA, around the eye has shown limited benefit. Some centres instead pass a catheter into the ophthalmic artery, as in stroke care, to deliver hyaluronidase and clot-dissolving drugs directly.
What the review found
The team searched PubMed, Scopus, Embase and Medline, added unpublished cases from task force members, and analysed 200 cases of intra-arterial therapy.
- Blood flow was fully or partly restored in 89.5%.
- Vision improved in only 40.0%.
- Patients who could still perceive light did better: 58.7% improved, against 34.4% of those with no light perception.
- Combining hyaluronidase with a thrombolytic drug was linked to better results than hyaluronidase alone (64.5% vs 35.5%).
The gap between reopened vessels and restored vision probably reflects how quickly retinal tissue dies without blood. The authors used the data, with stroke experience, to build consensus protocols for filler-induced blindness and orbital compromise.
Why it matters
For injectors, the message is that prevention and speed outweigh any rescue. The best results came in patients who still had some vision, which argues for immediate referral pathways to centres with interventional radiology. For patients, it is a reminder that eye-area and nose fillers carry a small risk of permanent harm, and that the injector’s training and emergency plan matter.
Limitations
This is a pooled analysis of published and solicited case reports, not a trial. Successful cases are more likely to be reported, so real-world results may be worse. Treatments, drugs, doses and timing varied between centres, and the abstract does not report time to treatment. The comparison between hyaluronidase alone and combination therapy is not randomised. The protocols rest on expert consensus. Funding and conflicts of interest were not visible, as the full text is behind a paywall.
Key takeaways
- In 200 intra-arterial treatments for filler blindness, vessels reopened in 89.5% but vision improved in 40%.
- Remaining light perception was linked to better recovery (58.7% vs 34.4%), underlining the value of speed.
- The new protocols are consensus-based; the evidence comes from case reports with likely reporting bias.
Sources
- Zhang-Nunes S, et al.; ISAC Vision Task Force. “New Protocols for Filler-induced Blindness and Orbital Compromise Based on Systematic Analysis of Intra-arterial Thrombolytic Stroke Treatment With an International Task Force.” Aesthetic Surgery Journal Open Forum, published online 6 Nov 2026. doi:10.1093/asjof/ojag222
Disclaimer: This article is published by Aesthetics.news for general information and educational purposes only. It does not constitute medical advice, diagnosis or treatment, and should not replace a consultation with a qualified healthcare professional. Treatments and outcomes may vary from person to person. Readers should seek advice from an appropriately qualified professional before making decisions about their health or treatment. In a medical emergency, seek immediate medical assistance.